THY1 and glioma: CD90 was recently identified as a prognostic marker for high-grade gliomas and CD44 as a marker of metastatic potential [17, 18] and coworkers [19] showed that aberrant expression of the cancer stem cell markers CD90 and CD44 contributes to tumoral progression.